Dr. Reddy's is lined up to copy 6 of the blockbuster drugs on this tracker, which earned $53.9B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Dr. Reddy's's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved Jan 2025 | $7.7B |
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved Aug 2026 | $2.7B |
| Jakafi | Incyte | Generic | 2028 | Settled, terms confidential | $3.1B |
| Ozempic | Novo Nordisk | Generic | 2032 | Settled, terms confidential | ≈$19.3B |
| Darzalex HLX15 |
Johnson & Johnson | Biosimilar | 2029 | Phase 1; first patient dosed May 2026 | $14.3B |
| Cosentyx BAT2306 |
Novartis | Biosimilar | 2029 | Phase 3 complete | $6.7B |
Company facts: SEC company tickers. Each drug page lists sources for these entries. Brand sales show the size of the market, not Dr. Reddy's's share of it.